ID   MP2K5_HUMAN             Reviewed;         448 AA.
AC   Q13163; B4DE43; Q92961; Q92962;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   28-NOV-2006, sequence version 2.
DT   12-OCT-2022, entry version 212.
DE   RecName: Full=Dual specificity mitogen-activated protein kinase kinase 5;
DE            Short=MAP kinase kinase 5;
DE            Short=MAPKK 5;
DE            EC=2.7.12.2;
DE   AltName: Full=MAPK/ERK kinase 5;
DE            Short=MEK 5;
GN   Name=MAP2K5; Synonyms=MEK5, MKK5, PRKMK5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A), FUNCTION, INTERACTION WITH ERK5 AND
RP   MAPK7, MUTAGENESIS OF LYS-195; SER-311 AND THR-315, AND PHOSPHORYLATION AT
RP   SER-311 AND THR-315.
RC   TISSUE=Fetal brain;
RX   PubMed=7759517; DOI=10.1074/jbc.270.21.12665;
RA   Zhou G., Bao Z.Q., Dixon J.E.;
RT   "Components of a new human protein kinase signal transduction pathway.";
RL   J. Biol. Chem. 270:12665-12669(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS B AND C), AND FUNCTION.
RC   TISSUE=Placenta;
RX   PubMed=9384584; DOI=10.1093/emboj/16.23.7054;
RA   Kato Y., Kravchenko V.V., Tapping R.I., Han J., Ulevitch R.J., Lee J.-D.;
RT   "BMK1/ERK5 regulates serum-induced early gene expression through
RT   transcription factor MEF2C.";
RL   EMBO J. 16:7054-7066(1997).
RN   [3]
RP   SEQUENCE REVISION TO C-TERMINUS OF ISOFORM C.
RA   Lee J.D.;
RL   Submitted (MAY-2007) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM B).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM B).
RA   Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S., Neubert P.,
RA   Kstrang K., Schatten R., Shen B., Henze S., Mar W., Korn B., Zuo D., Hu Y.,
RA   LaBaer J.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R., Fahey J.,
RA   Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G., Johnson E.,
RA   Jones C., Kamat A., Kaur A., Locke D.P., Madan A., Munson G., Jaffe D.B.,
RA   Lui A., Macdonald P., Mauceli E., Naylor J.W., Nesbitt R., Nicol R.,
RA   O'Leary S.B., Ratcliffe A., Rounsley S., She X., Sneddon K.M.B.,
RA   Stewart S., Sougnez C., Stone S.M., Topham K., Vincent D., Wang S.,
RA   Zimmer A.R., Birren B.W., Hood L., Lander E.S., Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human chromosome
RT   15.";
RL   Nature 440:671-675(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM B).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   INTERACTION WITH YOPJ (MICROBIAL INFECTION), AND ACETYLATION.
RX   PubMed=16728640; DOI=10.1126/science.1126867;
RA   Mukherjee S., Keitany G., Li Y., Wang Y., Ball H.L., Goldsmith E.J.,
RA   Orth K.;
RT   "Yersinia YopJ acetylates and inhibits kinase activation by blocking
RT   phosphorylation.";
RL   Science 312:1211-1214(2006).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-311, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 4-108 IN COMPLEX WITH MAP3K2.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of the complex of human mitogen activated protein kinase
RT   kinase 5 phox domain (MAP2K5-Phox) with human mitogen activated protein
RT   kinase kinase kinase 3 (MAP3K2B-Phox).";
RL   Submitted (NOV-2006) to the PDB data bank.
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.83 ANGSTROMS) OF 4-108 IN COMPLEX WITH MAP3K3.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of the complex of human mitogen activated protein kinase
RT   kinase 5 phox domain (MAP2K5-Phox) with human mitogen activated protein
RT   kinase kinase kinase 3 (MAP3K3B-Phox).";
RL   Submitted (NOV-2006) to the PDB data bank.
RN   [14]
RP   VARIANTS [LARGE SCALE ANALYSIS] ARG-118; VAL-427 AND THR-428.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Acts as a scaffold for the formation of a ternary
CC       MAP3K2/MAP3K3-MAP3K5-MAPK7 signaling complex. Activation of this
CC       pathway appears to play a critical role in protecting cells from
CC       stress-induced apoptosis, neuronal survival and cardiac development and
CC       angiogenesis. {ECO:0000269|PubMed:7759517, ECO:0000269|PubMed:9384584}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.12.2;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.12.2;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.12.2;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- SUBUNIT: Interacts with PARD6A, MAP3K3 and MAPK7. Forms a complex with
CC       SQSTM1 and PRKCZ or PRKCI (By similarity). {ECO:0000250,
CC       ECO:0000269|PubMed:7759517, ECO:0000269|Ref.12, ECO:0000269|Ref.13}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Yersinia YopJ.
CC       {ECO:0000269|PubMed:16728640}.
CC   -!- INTERACTION:
CC       Q13163; Q3SXR2: C3orf36; NbExp=3; IntAct=EBI-307294, EBI-18036948;
CC       Q13163; Q9H596: DUSP21; NbExp=3; IntAct=EBI-307294, EBI-7357329;
CC       Q13163; P62993: GRB2; NbExp=2; IntAct=EBI-307294, EBI-401755;
CC       Q13163; Q96NT3-2: GUCD1; NbExp=3; IntAct=EBI-307294, EBI-11978177;
CC       Q13163; P08238: HSP90AB1; NbExp=4; IntAct=EBI-307294, EBI-352572;
CC       Q13163; Q8N448: LNX2; NbExp=3; IntAct=EBI-307294, EBI-2340947;
CC       Q13163; Q9Y2U5: MAP3K2; NbExp=6; IntAct=EBI-307294, EBI-357393;
CC       Q13163; Q99759: MAP3K3; NbExp=4; IntAct=EBI-307294, EBI-307281;
CC       Q13163; Q13164: MAPK7; NbExp=7; IntAct=EBI-307294, EBI-1213983;
CC       Q13163; Q99471: PFDN5; NbExp=3; IntAct=EBI-307294, EBI-357275;
CC       Q13163; Q13501: SQSTM1; NbExp=5; IntAct=EBI-307294, EBI-307104;
CC       Q13163; Q9BUY5: ZNF426; NbExp=3; IntAct=EBI-307294, EBI-743265;
CC       Q13163; Q6ZNG0: ZNF620; NbExp=3; IntAct=EBI-307294, EBI-4395669;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=B;
CC         IsoId=Q13163-1; Sequence=Displayed;
CC       Name=A;
CC         IsoId=Q13163-2; Sequence=VSP_021825;
CC       Name=C;
CC         IsoId=Q13163-3; Sequence=VSP_021825, VSP_021826;
CC       Name=4;
CC         IsoId=Q13163-4; Sequence=VSP_043333;
CC   -!- TISSUE SPECIFICITY: Expressed in many adult tissues. Abundant in heart
CC       and skeletal muscle.
CC   -!- DOMAIN: Binds MAP3K2/MAP3K3 and MAPK7 via non-overlapping residues of
CC       the PB1 domain. This domain also mediates interactions with SQSTM1 and
CC       PARD6A (By similarity). {ECO:0000250}.
CC   -!- PTM: Activated by phosphorylation on Ser/Thr by MAP kinase kinase
CC       kinases. {ECO:0000250}.
CC   -!- PTM: (Microbial infection) Yersinia YopJ may acetylate Ser/Thr
CC       residues, preventing phosphorylation and activation, thus blocking the
CC       MAPK signaling pathway. {ECO:0000269|PubMed:16728640,
CC       ECO:0000269|PubMed:7759517}.
CC   -!- MISCELLANEOUS: [Isoform C]: Incomplete sequence. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U25265; AAA96146.1; -; mRNA.
DR   EMBL; U71087; AAB16851.1; -; mRNA.
DR   EMBL; U71088; AAB16852.2; -; mRNA.
DR   EMBL; BT006780; AAP35426.1; -; mRNA.
DR   EMBL; AK293459; BAG56954.1; -; mRNA.
DR   EMBL; CR542229; CAG47025.1; -; mRNA.
DR   EMBL; AC009292; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC016355; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC103753; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC008838; AAH08838.1; -; mRNA.
DR   CCDS; CCDS10224.1; -. [Q13163-1]
DR   CCDS; CCDS42051.1; -. [Q13163-2]
DR   CCDS; CCDS55970.1; -. [Q13163-4]
DR   RefSeq; NP_001193733.1; NM_001206804.1. [Q13163-4]
DR   RefSeq; NP_002748.1; NM_002757.3. [Q13163-2]
DR   RefSeq; NP_660143.1; NM_145160.2. [Q13163-1]
DR   PDB; 2NPT; X-ray; 1.75 A; A/C=5-108.
DR   PDB; 2O2V; X-ray; 1.83 A; A=5-108.
DR   PDB; 4IC7; X-ray; 2.60 A; B/E=16-130.
DR   PDBsum; 2NPT; -.
DR   PDBsum; 2O2V; -.
DR   PDBsum; 4IC7; -.
DR   AlphaFoldDB; Q13163; -.
DR   SMR; Q13163; -.
DR   BioGRID; 111593; 99.
DR   CORUM; Q13163; -.
DR   DIP; DIP-27558N; -.
DR   IntAct; Q13163; 65.
DR   MINT; Q13163; -.
DR   STRING; 9606.ENSP00000178640; -.
DR   BindingDB; Q13163; -.
DR   ChEMBL; CHEMBL4948; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q13163; -.
DR   GuidetoPHARMACOLOGY; 2066; -.
DR   iPTMnet; Q13163; -.
DR   PhosphoSitePlus; Q13163; -.
DR   BioMuta; MAP2K5; -.
DR   DMDM; 118572669; -.
DR   CPTAC; CPTAC-818; -.
DR   CPTAC; CPTAC-819; -.
DR   EPD; Q13163; -.
DR   jPOST; Q13163; -.
DR   MassIVE; Q13163; -.
DR   MaxQB; Q13163; -.
DR   PaxDb; Q13163; -.
DR   PeptideAtlas; Q13163; -.
DR   PRIDE; Q13163; -.
DR   ProteomicsDB; 59199; -. [Q13163-1]
DR   ProteomicsDB; 59200; -. [Q13163-2]
DR   ProteomicsDB; 59201; -. [Q13163-3]
DR   ProteomicsDB; 59202; -. [Q13163-4]
DR   Antibodypedia; 26267; 610 antibodies from 36 providers.
DR   DNASU; 5607; -.
DR   Ensembl; ENST00000178640.10; ENSP00000178640.5; ENSG00000137764.20. [Q13163-1]
DR   Ensembl; ENST00000354498.9; ENSP00000346493.5; ENSG00000137764.20. [Q13163-4]
DR   Ensembl; ENST00000395476.6; ENSP00000378859.2; ENSG00000137764.20. [Q13163-2]
DR   GeneID; 5607; -.
DR   KEGG; hsa:5607; -.
DR   MANE-Select; ENST00000178640.10; ENSP00000178640.5; NM_145160.3; NP_660143.1.
DR   UCSC; uc002aqu.4; human. [Q13163-1]
DR   CTD; 5607; -.
DR   DisGeNET; 5607; -.
DR   GeneCards; MAP2K5; -.
DR   HGNC; HGNC:6845; MAP2K5.
DR   HPA; ENSG00000137764; Low tissue specificity.
DR   MIM; 602520; gene.
DR   neXtProt; NX_Q13163; -.
DR   OpenTargets; ENSG00000137764; -.
DR   PharmGKB; PA30590; -.
DR   VEuPathDB; HostDB:ENSG00000137764; -.
DR   eggNOG; KOG0581; Eukaryota.
DR   GeneTree; ENSGT00940000157505; -.
DR   HOGENOM; CLU_000288_2_0_1; -.
DR   InParanoid; Q13163; -.
DR   OMA; ILANGQX; -.
DR   OrthoDB; 81952at2759; -.
DR   PhylomeDB; Q13163; -.
DR   TreeFam; TF106468; -.
DR   BRENDA; 2.7.12.2; 2681.
DR   PathwayCommons; Q13163; -.
DR   Reactome; R-HSA-198765; Signalling to ERK5.
DR   SignaLink; Q13163; -.
DR   SIGNOR; Q13163; -.
DR   BioGRID-ORCS; 5607; 19 hits in 1114 CRISPR screens.
DR   ChiTaRS; MAP2K5; human.
DR   EvolutionaryTrace; Q13163; -.
DR   GeneWiki; MAP2K5; -.
DR   GenomeRNAi; 5607; -.
DR   Pharos; Q13163; Tchem.
DR   PRO; PR:Q13163; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   RNAct; Q13163; protein.
DR   Bgee; ENSG00000137764; Expressed in right testis and 202 other tissues.
DR   ExpressionAtlas; Q13163; baseline and differential.
DR   Genevisible; Q13163; HS.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0005819; C:spindle; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004708; F:MAP kinase kinase activity; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; ISS:BHF-UCL.
DR   GO; GO:0071499; P:cellular response to laminar fluid shear stress; TAS:BHF-UCL.
DR   GO; GO:0070375; P:ERK5 cascade; IEA:Ensembl.
DR   GO; GO:0007507; P:heart development; IEA:Ensembl.
DR   GO; GO:0000165; P:MAPK cascade; IBA:GO_Central.
DR   GO; GO:0090051; P:negative regulation of cell migration involved in sprouting angiogenesis; ISS:BHF-UCL.
DR   GO; GO:2000342; P:negative regulation of chemokine (C-X-C motif) ligand 2 production; ISS:BHF-UCL.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; ISS:BHF-UCL.
DR   GO; GO:2001240; P:negative regulation of extrinsic apoptotic signaling pathway in absence of ligand; ISS:BHF-UCL.
DR   GO; GO:0034115; P:negative regulation of heterotypic cell-cell adhesion; ISS:BHF-UCL.
DR   GO; GO:0032717; P:negative regulation of interleukin-8 production; ISS:BHF-UCL.
DR   GO; GO:0032088; P:negative regulation of NF-kappaB transcription factor activity; ISS:BHF-UCL.
DR   GO; GO:0060761; P:negative regulation of response to cytokine stimulus; ISS:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; ISS:BHF-UCL.
DR   GO; GO:0030307; P:positive regulation of cell growth; IEA:Ensembl.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; ISS:BHF-UCL.
DR   GO; GO:0051247; P:positive regulation of protein metabolic process; ISS:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISS:BHF-UCL.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   CDD; cd06395; PB1_Map2k5; 1.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000270; PB1_dom.
DR   InterPro; IPR034851; PB1_MAP2K5.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00564; PB1; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00666; PB1; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51745; PB1; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding; Kinase;
KW   Magnesium; Metal-binding; Nucleotide-binding; Phosphoprotein;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase;
KW   Tyrosine-protein kinase.
FT   CHAIN           1..448
FT                   /note="Dual specificity mitogen-activated protein kinase
FT                   kinase 5"
FT                   /id="PRO_0000086383"
FT   DOMAIN          18..109
FT                   /note="PB1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01081"
FT   DOMAIN          166..409
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          18..25
FT                   /note="Interaction with MAPK7"
FT                   /evidence="ECO:0000250"
FT   REGION          64..68
FT                   /note="Interaction with MAP3K2/MAP3K3"
FT                   /evidence="ECO:0000250"
FT   REGION          116..144
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          117..131
FT                   /note="Interaction with MAPK7"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        123..144
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        283
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         172..180
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         195
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   MOD_RES         311
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:7759517,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         315
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:7759517"
FT   VAR_SEQ         1..45
FT                   /note="MLWLALGPFPAMENQVLVIRIKIPNSGAVDWTVHSGPQLLFRDVL -> MME
FT                   GHFPQS (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_043333"
FT   VAR_SEQ         349..358
FT                   /note="Missing (in isoform A and isoform C)"
FT                   /evidence="ECO:0000303|PubMed:7759517,
FT                   ECO:0000303|PubMed:9384584"
FT                   /id="VSP_021825"
FT   VAR_SEQ         444..448
FT                   /note="QQGPP -> LASLPSPSPSV (in isoform C)"
FT                   /evidence="ECO:0000303|PubMed:9384584"
FT                   /id="VSP_021826"
FT   VARIANT         118
FT                   /note="H -> R (in dbSNP:rs56241934)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040823"
FT   VARIANT         427
FT                   /note="A -> V (in dbSNP:rs1226964455)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040824"
FT   VARIANT         428
FT                   /note="A -> T (in dbSNP:rs55811347)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_046070"
FT   MUTAGEN         195
FT                   /note="K->M: Inactivation."
FT                   /evidence="ECO:0000269|PubMed:7759517"
FT   MUTAGEN         311
FT                   /note="S->A: Inactivation."
FT                   /evidence="ECO:0000269|PubMed:7759517"
FT   MUTAGEN         315
FT                   /note="T->A: Inactivation."
FT                   /evidence="ECO:0000269|PubMed:7759517"
FT   STRAND          17..23
FT                   /evidence="ECO:0007829|PDB:2NPT"
FT   TURN            24..26
FT                   /evidence="ECO:0007829|PDB:2NPT"
FT   STRAND          27..33
FT                   /evidence="ECO:0007829|PDB:2NPT"
FT   HELIX           41..51
FT                   /evidence="ECO:0007829|PDB:2NPT"
FT   STRAND          58..63
FT                   /evidence="ECO:0007829|PDB:2NPT"
FT   STRAND          65..67
FT                   /evidence="ECO:0007829|PDB:4IC7"
FT   STRAND          69..72
FT                   /evidence="ECO:0007829|PDB:2NPT"
FT   HELIX           75..93
FT                   /evidence="ECO:0007829|PDB:2NPT"
FT   TURN            94..96
FT                   /evidence="ECO:0007829|PDB:2NPT"
FT   STRAND          102..107
FT                   /evidence="ECO:0007829|PDB:2NPT"
SQ   SEQUENCE   448 AA;  50112 MW;  F23BB327E2A9C7DC CRC64;
     MLWLALGPFP AMENQVLVIR IKIPNSGAVD WTVHSGPQLL FRDVLDVIGQ VLPEATTTAF
     EYEDEDGDRI TVRSDEEMKA MLSYYYSTVM EQQVNGQLIE PLQIFPRACK PPGERNIHGL
     KVNTRAGPSQ HSSPAVSDSL PSNSLKKSSA ELKKILANGQ MNEQDIRYRD TLGHGNGGTV
     YKAYHVPSGK ILAVKVILLD ITLELQKQIM SELEILYKCD SSYIIGFYGA FFVENRISIC
     TEFMDGGSLD VYRKMPEHVL GRIAVAVVKG LTYLWSLKIL HRDVKPSNML VNTRGQVKLC
     DFGVSTQLVN SIAKTYVGTN AYMAPERISG EQYGIHSDVW SLGISFMELA LGRFPYPQIQ
     KNQGSLMPLQ LLQCIVDEDS PVLPVGEFSE PFVHFITQCM RKQPKERPAP EELMGHPFIV
     QFNDGNAAVV SMWVCRALEE RRSQQGPP
//
